All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Recent Approvals Across Hematologic Malignancies Usher in a New Era

February 14th 2024

Mikkael A. Sekeres, MD, MS, highlights recent approvals and emerging therapeutics in hematologic malignancies discussed by his colleagues.

Standard-of-Care Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies

February 13th 2024

Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.

McAndrew Expands on the Evolving Treatment Armamentarium in HER2+ Breast Cancer

February 13th 2024

Nicholas P. McAndrew, MD, MSCE, discusses how updated clinical trial findings are shifting the treatment paradigm in HER2-positive metastatic breast cancer.

FDA Approves Frontline NALIRIFOX for Metastatic Pancreatic Adenocarcinoma

February 13th 2024

The FDA has approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the frontline treatment of metastatic pancreatic adenocarcinoma.

Rutgers Cancer Institute of New Jersey Unveils Leadership Enhancements for Next Era of Excellence

February 13th 2024

Rutgers Cancer Institute of New Jersey has elevated 2 associate director functions to deputy director positions.

FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma

February 13th 2024

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

FDA Accepts NDA Resubmission for Dasynoc in CML

February 13th 2024

A new drug application for Dasynoc, a protein kinase inhibitor product candidate for patients with chronic myeloid leukemia, has been accepted by the FDA.

APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC

February 13th 2024

John Shen, MD, discusses the phase 1/2 APEX-01 trial of ARX517 in metastatic castration-resistant prostate cancer.

Long-Term CheckMate 238 Data Support Adjuvant Nivolumab Vs Ipilimumab in Resected Melanoma

February 13th 2024

Adjuvant nivolumab significantly improved relapse-free survival vs ipilimumab in resected stage III/IV melanoma, according to 7-year minimum follow-up.

FDA Grants Fast Track Designation to BXCL701 for Small Cell Neuroendocrine Prostate Cancer

February 12th 2024

BXCL701 has been granted fast track designation for select patients with metastatic small cell neuroendocrine prostate cancer by the FDA.

Emavusertib Demonstrates Safety, Early Antitumor Activity in Select Patients With FLT3-Mutant R/R AML

February 12th 2024

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

FELIX Pooled Analysis Findings Potentiate Further Obe-Cel Development in B-ALL

February 12th 2024

Michael R. Bishop, MD, discusses the rationale for and key findings from the FELIX trial of obe-cel in B-cell acute lymphoblastic leukemia.

NCCN Releases First Neuroblastoma Treatment Recommendations

February 12th 2024

The NCCN has published the first set of treatment recommendations for neuroblastoma.

Florida Cancer Specialists & Research Institute Appoints Joel Grossman, MD and Maen Hussein, MD to Executive Board

February 12th 2024

Florida Cancer Specialists & Research Institute, LLC announces the appointments of Joel Grossman, MD and Maen Hussein, MD to its Executive Board.

FDA Grants Breakthrough Therapy Designation to AlphaMedix for Gastroenteropancreatic Neuroendocrine Tumors

February 12th 2024

AlphaMedix has received breakthrough therapy designation from the FDA for use in select patients with gastroenteropancreatic neuroendocrine tumors.

Omission in Breast Cancer: When to Leave Radiation Behind and How to Mitigate Disparities

February 12th 2024

Reshma Jagsi, MD, DPhil, details advances from 2023 in breast cancer radiation oncology and interventions aimed at combating disparities within oncology.

Chest CT Imaging Patterns Contradict ACR Guidelines for Extremity Sarcoma Staging and Surveillance

February 10th 2024

R. Lor Randall, MD, FACS, explains the next steps in ensuring adherence to clinical care guidelines in extremity sarcoma.

rPFS and cPFS May Act as Surrogate OS End Points in Phase 3 mHSPC Clinical Trials

February 9th 2024

Radiographic and clinical progression-free survival may be surrogates for overall survival in hormone-sensitive prostate cancer clinical trials.

Addressing Patient-Provider Communication Challenges is Vital for Improved Breast Cancer Care

February 9th 2024

Jane L. Meisel, MD, highlighted patient-reported gaps in provider communication regarding treatment-related toxicities in metastatic breast cancer.

Trabectedin Monotherapy Does Not Improve OS vs Chemotherapy in BRCA-Mutated Recurrent Ovarian Cancer

February 9th 2024

Trabectedin did not offer a survival benefit vs chemotherapy in recurrent ovarian cancer with BRCA-mutated and/or BRCAness phenotype.